Anticoagulants are recommended for atrial fibrillation due to the high risk of stroke.
Researchers in Japan examined several types of anticoagulants and found that the rates of thrombus formation are different according to the type of drug.
Atrial fibrillation is an arrhythmia signified by rapid and irregular beating of the upper chambers of the heart (atria).
Anticoagulant therapy is recommended for atrial fibrillation because thrombi formed by stagnated blood in the atrium can cause stroke.
Fortunately, DOACs are known to have less incidence of intracranial bleeding and fewer incidents of hematoma than warfarin.
Although the DOAC mechanisms responsible for reduced intracranial bleeding compared to warfarin have been investigated in animal experiments, they have not yet been fully elucidated.